CARRIE STIRN: Open Payments
NPI 1568043677 · RICHMOND, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,040 in 73 payments from 13 companies in 2025. Trend: 2023 $1,032 · 2024 $1,709 · 2025 $1,040
Food & beverage: $1,040
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $265 |
| Novo Nordisk Inc | 16 | $229 |
| AstraZeneca Pharmaceuticals LP | 9 | $202 |
| Lilly USA, LLC | 5 | $73 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $47 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $37 |
| GlaxoSmithKline, LLC. | 2 | $35 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $30 |
| PFIZER INC. | 2 | $28 |
| Supernus Pharmaceuticals, Inc. | 2 | $28 |
Products named: Ozempic, QULIPTA, JARDIANCE, VRAYLAR, BREZTRI, FARXIGA, UBRELVY, Kerendia.
Industry payments across IN — which companies pay providers there.
